The Auscann Group Holdings Ltd (ASX: AC8) share price was down 4% to $1.68 on Friday, after the stock had climbed 25% higher during the week.
While the main driver of the price surge was the announcement that the company received an import permit to source medicinal cannabis products from Canadian company Canopy Growth Corporation, on Thursday Auscann released a report summarising progress made in the March 2018 quarter.
Auscann and its partner Tasmanian Alkaloid expect to plant their first Australian crop this year, and to have products available by early 2019. Auscann signed an agreement with Australian Pharmaceutical Industries Ltd (ASX: API) for the domestic distribution of its products, but the company is also looking at export markets.
In fact, at the beginning of January, Auscann’s share price skyrocketed on the news that the federal government would permit the export of cannabinoid medicines from Australia.
In the meantime, Chilean authorities have granted patients immediate access to medicinal cannabis. Auscann operates in Chile through Dayacann, a joint venture with the local Fundación Daya.
Auscann spent $1.5 million during the quarter, and $400,000 in R&D. This leaves a $12 million cash balance, enough to continue operations while looking forward to the first sales.
Follow the free link below to find out about the other innovative companies that are poised to outperform the market in 2018.
We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.
That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.
We’ve found three exciting companies that we believe are poised to perform in the new year. Click here to uncover these ideas!
Motley Fool contributor Tommaso Autorino has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.